list : Cancer
-
Cancer drug renders COVID vaccine ineffective
Rituximab, a drug widely used in patients with lymphoma, blunts or eliminates the antibody response to COVID-19 vaccines if it is administered before them, Stanford researchers say.
-
Antibody synergy targets tough cancers
Two anti-cancer antibodies have a much stronger effect against pediatric nerve-cell and bone cancers in mice than either one alone, researchers have discovered.
-
Major grant renewal for Stanford Cancer Institute
The Stanford Cancer Institute is one of 51 National Cancer Institute-designated comprehensive cancer centers, which must meet rigorous standards for improving the prevention, diagnosis and treatment of cancer.
-
Hematologist Steven Coutre dies
Steven Coutre was known for his research on chronic lymphocytic leukemia, his humility and his love of traveling and family.
-
Study: COVID-19 vaccine effective in cancer patients
The Moderna and Pfizer BioNTech vaccines prevented COVID-19 infection in cancer patients, particularly in those whose treatment concluded more than six months before vaccination, say researchers at Stanford, Harvard and the VA.
-
New immunotherapy targets tumors
Stanford researchers have developed a synthetic, tumor-targeting molecule that promotes immune activation and tumor regression in laboratory mice after it’s injected into their bloodstreams.
-
$12 million for stem cell trial
Stanford researcher Maria Grazia Roncarolo has been awarded $12 million by the California Institute for Regenerative Medicine for a trial aimed at improving the outcomes of stem cell transplants in children and young adults with blood cancers.
-
Identifying new types of cancer cells
EcoTyper is an algorithm that can sort out cell “ecotypes” — distinct multicellular communities — that exist in many different kinds of cancer.
-
Breast cancer mutations don’t lower survival rates
Newly diagnosed breast or ovarian cancer patients who carry common cancer-associated mutations have similar or better short-term survival rates than those with no mutations, researchers report.
-
$31 million for stem cell clinical trials
The California Institute for Regenerative Medicine has awarded $31 million to three Stanford researchers to launch trials of treatments for common diseases. Four other Stanford researchers also received a total of $4.55 million.